Review



skmel5 cell line  (Array BioPharma)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Array BioPharma skmel5 cell line
    (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) <t>for</t> <t>IPC298</t> <t>CLX.</t> (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
    Skmel5 Cell Line, supplied by Array BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel5+cell+line/skmel5+cell+line/bio_rxiv__2022__01__10__475285-173-10-18
    Average 90 stars, based on 1 article reviews
    skmel5 cell line - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas"

    Article Title: MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

    Journal: bioRxiv

    doi: 10.1101/2022.01.10.475285

    (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for IPC298 CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
    Figure Legend Snippet: (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for IPC298 CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.

    Techniques Used: Expressing, Inhibition, Standard Deviation

    Related Articles

    Expressing:

    Article Title: MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
    Article Snippet: SKMEL5, SKMEL28, SKMEL2, and IPC298 cell lines were used for cell line xenograft (CLX) analyses in collaboration with Array Biopharma.

    Inhibition:

    Article Title: MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
    Article Snippet: SKMEL5, SKMEL28, SKMEL2, and IPC298 cell lines were used for cell line xenograft (CLX) analyses in collaboration with Array Biopharma.

    Standard Deviation:

    Article Title: MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
    Article Snippet: SKMEL5, SKMEL28, SKMEL2, and IPC298 cell lines were used for cell line xenograft (CLX) analyses in collaboration with Array Biopharma.



    Similar Products

    skmel5 cell lines  (ATCC)
    96
    ATCC skmel5 cell lines
    Skmel5 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel5+cell+line/SK-MEL-5/pm41176765-218-5-11
    Average 96 stars, based on 1 article reviews
    skmel5 cell lines - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    cell line skmel5  (ATCC)
    96
    ATCC cell line skmel5
    Cell Line Skmel5, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel5+cell+line/SK-MEL-5/pm37105726-150-0-6
    Average 96 stars, based on 1 article reviews
    cell line skmel5 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    skmel5 cell line  (ATCC)
    96
    ATCC skmel5 cell line
    Skmel5 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel5+cell+line/SK-MEL-5/bio_rxiv__2022__02__03__479045-158-0-6
    Average 96 stars, based on 1 article reviews
    skmel5 cell line - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    skmel5 cell line  (Array BioPharma)
    90
    Array BioPharma skmel5 cell line
    (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) <t>for</t> <t>IPC298</t> <t>CLX.</t> (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
    Skmel5 Cell Line, supplied by Array BioPharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel5+cell+line/skmel5+cell+line/bio_rxiv__2022__01__10__475285-173-10-18
    Average 90 stars, based on 1 article reviews
    skmel5 cell line - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    melanoma cell lines skmel5  (ATCC)
    96
    ATCC melanoma cell lines skmel5
    (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) <t>for</t> <t>IPC298</t> <t>CLX.</t> (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
    Melanoma Cell Lines Skmel5, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel5+cell+line/SK-MEL-5/pmc07370234-32-0-4
    Average 96 stars, based on 1 article reviews
    melanoma cell lines skmel5 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    human melanoma cell line skmel5 htb 70  (ATCC)
    96
    ATCC human melanoma cell line skmel5 htb 70
    (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) <t>for</t> <t>IPC298</t> <t>CLX.</t> (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
    Human Melanoma Cell Line Skmel5 Htb 70, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel5+cell+line/SK-MEL-5/pmc06435720-21-1-11
    Average 96 stars, based on 1 article reviews
    human melanoma cell line skmel5 htb 70 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    skmel5 melanoma cell line  (Inserm Transfert)
    90
    Inserm Transfert skmel5 melanoma cell line
    (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) <t>for</t> <t>IPC298</t> <t>CLX.</t> (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
    Skmel5 Melanoma Cell Line, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel5+cell+line/skmel5+melanoma+cell+line/pm21441454-58-18-25
    Average 90 stars, based on 1 article reviews
    skmel5 melanoma cell line - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    skmel5 melanoma cell line  (ATCC)
    96
    ATCC skmel5 melanoma cell line
    (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) <t>for</t> <t>IPC298</t> <t>CLX.</t> (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.
    Skmel5 Melanoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/skmel5+cell+line/SK-MEL-5/10__1523_slash_jneurosci__19___14___05942__1999-45-4-12
    Average 96 stars, based on 1 article reviews
    skmel5 melanoma cell line - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for IPC298 CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.

    Journal: bioRxiv

    Article Title: MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

    doi: 10.1101/2022.01.10.475285

    Figure Lengend Snippet: (A) Experimental setup for cell line xenograft studies of mice + binimetinib or encorafinib. X-axis describes days of therapy and drug treatment (M=MEKi, binimetinib and B=BRAFi, encorafinib). (B) Volcano plot, average fold change in pMHC expression with binimetinib treatment (n=3 biological replicates for DMSO and MEKi treated cells) versus significance (mean-adjusted p value, unpaired two-sided t test) for IPC298 CLX. (C) Violin plot of distribution of fold changes in presentation of pMHCs following MEK inhibition (M, binimetinib), BRAF inhibition (B, encorafinib) or both (B/M). Solid line represents median, dotted lines define the first and third quartiles. (D) TAA enrichment significance values for each analysis. Black dotted line represents p≥0.05, grey = p≥0.01. (E) Changes in pMHC expression for select melanoma differentiation antigens. Errors bars represent standard deviation when >1 peptide from each source protein was identified.

    Article Snippet: SKMEL5, SKMEL28, SKMEL2, and IPC298 cell lines were used for cell line xenograft (CLX) analyses in collaboration with Array Biopharma.

    Techniques: Expressing, Inhibition, Standard Deviation